Description

Zucarfil (Carfilzomib Injection 60 mg) – Product Description Zucarfil contains Carfilzomib 60 mg, a targeted anti-cancer medicine used for the treatment of relapsed or refractory multiple myeloma (RRMM). It belongs to the proteasome inhibitor class of medicines and works by irreversibly blocking the 20S proteasome, causing the accumulation of damaged proteins within cancer cells. This leads to cellular stress and programmed cancer cell death (apoptosis), helping slow disease progression. Zucarfil is supplied as a lyophilized powder for intravenous (IV) infusion and is administered by qualified healthcare professionals. It is commonly used in combination with medicines such as dexamethasone, lenalidomide, or daratumumab, depending on the patient's treatment regimen and clinical condition. Active Ingredient Carfilzomib 60 mg Dosage Form Lyophilized Powder for Injection (IV Infusion) Therapeutic Indications Relapsed Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma Combination Therapy Other approved indications as determined by the treating oncologist How It Works Carfilzomib selectively and irreversibly inhibits the 20S proteasome, preventing the breakdown of unwanted proteins inside cancer cells. The resulting protein buildup disrupts normal cell function, triggering apoptosis and reducing the growth of multiple myeloma cells. Key Features Targeted proteasome inhibitor for multiple myeloma Effective in relapsed and refractory disease Administered by intravenous infusion under specialist supervision Commonly used in combination with established myeloma therapies Manufactured according to stringent pharmaceutical quality standards Storage Store refrigerated at 2°C–8°C. Protect from light and do not freeze. Keep out of reach of children. Note: Zucarfil (Carfilzomib Injection 60 mg) is a prescription-only medicine and should be administered only by qualified healthcare professionals experienced in oncology. Patients should be monitored regularly for blood counts, kidney function, liver function, cardiac status, and infusion-related reactions throughout treatment.